Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3982091 | 1.00 | CTSK (0.45) | CTSKNR1H4ABCB1TSHRKMT2A | |
| SCHEMBL1269661 | 1.00 | CTSK (0.45) | CTSKNR1H4ABCB1TSHRKMT2A | |
| SCHEMBL505999 | 0.86 | NR1H4 (0.60) | CTSKNR1H4ABCB1TSHRKMT2A | |
| SCHEMBL506000 | 0.86 | NR1H4 (0.60) | CTSKNR1H4ABCB1TSHRKMT2A | |
| SCHEMBL4095177 | 0.86 | NR1H4 (0.60) | CTSKNR1H4ABCB1TSHRKMT2A | |
| SCHEMBL17524451 | 0.86 | NAMPT (0.53) | CTSKABCB1KMT2ALMNACYP3A4 | |
| SCHEMBL6385504 | 0.85 | CA1 (0.45) | TSHRCYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL14566800 | 0.83 | ABCB1 (0.58) | CTSKABCB1ALDH1A1CA1CA2 | |
| SCHEMBL29219606 | 0.83 | ABCB1 (0.58) | CTSKABCB1ALDH1A1CA1CA2 | |
| SCHEMBL15609314 | 0.83 | CTSK (0.45) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148274-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| CN-110291085-B | Mutant isocitrate dehydrogenase inhibitors, compositions and methods thereof | 艾科生物科技有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-11370758-B2 | IDO-TDO dual inhibitor and related methods of use | CMG PHARMACEUTICAL CO., LTD. (KR) | 2022-06-28 | — | — | US | disclosed |
| WO-2019180686-A1 | IDO-TDO DUAL INHIBITOR AND RELATED METHODS OF USE | CMG PHARMACEUTICAL CO., LTD. (KR) | 2019-09-26 | — | — | WO | disclosed |
| US-20190292150-A1 | IDO-TDO DUAL INHIBITOR AND RELATED METHODS OF USE | CMG PHARMACEUTICAL CO., LTD. (KR) | 2019-09-26 | — | — | US | disclosed |
| EP-2771337-B1 | 3-(PYRIMIDIN-4-YL)-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| CN-104411684-B | Phenoxyethyl piperidine compounds | 伊莱利利公司 | 2016-08-24 | — | — | CN | disclosed |
| EP-2649061-B1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-05-13 | — | — | EP | disclosed |
| CN-104411684-A | Phenoxyethyl piperidine compounds | LILLY CO ELI | 2015-03-11 | — | — | CN | disclosed |
| US-8957068-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2015-02-17 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-20100234387-A1 | Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals | GRUENETHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| WO-2010099938-A1 | SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS | Grünenthal GmbH (DE) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
| EP-1756043-B1 | ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS | RAQUALIA PHARMA INC (JP) | 2009-07-01 | — | — | EP | disclosed |
| WO-2005102389-A9 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234387-A1 | Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals | BDKRB1, BDKRB2, KCNB1 | CTSK 1392/4885NR1H4 2265/4885ABCB1 296/4885 |
| US-20190292150-A1 | IDO-TDO DUAL INHIBITOR AND RELATED METHODS OF USE | IDO1, IDO2, TDO2 | CTSK 1544/4885NR1H4 1754/4885ABCB1 1561/4885 |
| US-11370758-B2 | IDO-TDO dual inhibitor and related methods of use | IDO1, IDO2, TDO2 | CTSK 1544/4885NR1H4 1754/4885ABCB1 1561/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | CTSK 1031/4885NR1H4 936/4885ABCB1 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.